Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.

Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.

Item
http://www.wikidata.org/entity/Q40971062
Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphomaImmune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.Cytoplasmic expression of C-MYC protein is associated with risk stratification of mantle cell lymphoma.PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.Programmed death-ligand 1 is upregulated in intrahepatic lymphoepithelioma-like cholangiocarcinomaMechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.B-Cell and Classical Hodgkin Lymphomas Associated With Immunodeficiency: 2015 SH/EAHP Workshop Report-Part 2.The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.Immunodeficiency and Dysregulation: Report of the 2015 Workshop of the Society for Hematopathology/European Association for Haematopathology.PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients.Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.Cancer Immunotherapy in Diffuse Large B-Cell LymphomaNew developments in immunotherapy for lymphomaThe prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis
P2860

Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.

Item
http://www.wikidata.org/entity/Q40971062
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Clinicopathological analysis o ...... iffuse large B cell lymphomas.
@en
type
label
Clinicopathological analysis o ...... iffuse large B cell lymphomas.
@en
prefLabel
Clinicopathological analysis o ...... iffuse large B cell lymphomas.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Clinicopathological analysis o ...... iffuse large B cell lymphomas.
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P698